X
[{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US FDA Grants Once Daily Dosing Option for NITYR (nitisinone) Tablets for HT-1 Patients","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cycle Pharmaceuticals Launches SAJAZIRTM (icatibant) Injection, A New Treatment Option in Hereditary Angioedema (HAE)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Multiple Sclerosis Patients in US Left Without Essential Patient Support Program Will Now Receive Equivalent Backing From Cycle Pharmaceuticals Following FDA\u2019s Approval of TASCENSO ODT\u00ae (fingolimod)","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Drug, Tascenso ODT\u00ae (fingolimod), Launched to Meet the Needs of Multiple Sclerosis Patients in the US Left Without Essential Patient Support","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase IV"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New US Product, ORMALVI\u2122 (dichlorphenamide) Tablets, Launches for Primary Periodic Paralysis (PPP) Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase IV"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Tiopronin Delayed-Release Tablets Launch For Cystinuria Treatment","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Phase IV","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Nephrology","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals by Cycle Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. It is indicated for cystinuria.
Lead Product(s):
Tiopronin
Therapeutic Area: Nephrology
Product Name: Tiopronin-Generic
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Torrent Pharmaceuticals Limited
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 13, 2024
Details:
Ormalvi (dichlorphenamide) is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Lead Product(s):
Dichlorphenamide
Therapeutic Area: Genetic Disease
Product Name: Ormalvi
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Torrent Pharmaceuticals Limited
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 08, 2024
Details:
Tascenso (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
Lead Product(s):
Fingolimod Hydrochloride
Therapeutic Area: Neurology
Product Name: Tascenso
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 13, 2023
Details:
Tascenso (fingolimod) is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of MS, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.
Lead Product(s):
Fingolimod Hydrochloride
Therapeutic Area: Neurology
Product Name: Tascenso
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 17, 2023
Details:
SAJAZIR™ is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Lead Product(s):
Icatibant Acetate
Therapeutic Area: Genetic Disease
Product Name: Sajazir
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 28, 2021
Details:
NITYR® is indicated for the treatment of patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Lead Product(s):
Nitisinone
Therapeutic Area: Genetic Disease
Product Name: Nityr
Highest Development Status: Phase IV
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 14, 2020